Abstract
Blood flow can be restored to limbs after 1 to 2 hours of ischemia with the expectation that the limbs will survive and be functional. Adverse changes may occur during reperfusion of skeletal muscle which has been ischemic for 3 hours or more. These changes, ischemia-reperfusion injury (IRI), can include endothelial cell swelling, increased micròvascular permeability, leukocyte endothelial adhesion, vascular thrombosis, altered vascular resistance, no reflow phenomenon, altered monocyte/neutrophil function and even death of the ischemic reperfused cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adams J, Dhar A, Kikta M, et al. Role of platelet-activating factor in skeletal muscle ischemia reperfusion injury. Surg Forum:XLV; 395–397, 1994.
Adams J, Dhar A, Shukla S, Silver D. Effect of pentoxifylline on tissue injury and platelet-activating factor production during ischemia-reperfusion injury. JVS: 2I (5); 742–749, 1995.
Stefanovich V, Jarvis P, Grigoleit HG. The effect of pentoxifylline on the 3’,5’-cyclic AMP-system in bovine platelets. Int J Biochem: 8; 359–364, 1977.
Hammerschmidt D, Kotasek D, McCarthy T, et al.Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med: 112; 254–263, 1988.
Berens K, Luke D. Pentoxifylline in the isolated perfused rat kidney. Transplantation: 49; 876–879, 1990.
Bluhm R, Molnar J, Cohen M. The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain. Clin Neuropharmaco1: 8; 280–285, 1985.
Satewachin I, Iljin V, Schestakov V, et al. The use of pentoxifylline in a combined regimen for the prevention of re-thrombosis in major blood vessels. Pharmatherapeutica:2 Suppl 1; 109–117, 1978.
Weithmann K. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic amp. Gen Pharmac: 14; 161–162, 1983.
Schror K, Matzky R, Kahlen T, Darius H. The release of prostacyclin (PGI2) by pentoxyfylline from human and animal vascular tissue and its implications for vascular and antiplatelet activities. Thromb Haemost: 46; 272, 1981.
Lorant D, Patel K, McIntyre T, et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biology: 115; 223–234, 1991.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Silver, D., Dhar, A., Slocum, M., Adams, J.G., Shukla, S. (1996). Role of Platelet-Activating Factor in Skeletal Muscle Ischemia-Reperfusion Injury. In: Nigam, S., Kunkel, G., Prescott, S.M. (eds) Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology, vol 416. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0179-8_35
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0179-8_35
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0181-1
Online ISBN: 978-1-4899-0179-8
eBook Packages: Springer Book Archive